68Ga-FAPI PET/CT may be Better than 18F-FDG PET/CT for Staging Lung Cancer
A prospective study published in Radiology suggests that 68Ga-labeled fibroblast-activation protein inhibitor (FAPI) PET/CT may be better than 18F-labeled FDG PET/CT for staging lung cancer, especially in detecting metastases in the lymph nodes, brain, bone and pleura.
Researchers from the Nanfang PET Center, Nanfang Hospital of Southern Medical University (Guangzhou, China) evaluated 34 patients with a median age of 64 who underwent both 68Ga-FAPI PET/CT and 18F-FDG PET/CT. While the two modalities performed similarly for primary or recurrent tumors in the lung, the authors found 68Ga-FAPI PET/CT depicted more positive lymph nodes (356 vs. 320) and more distant metastases (255 vs 193) than 18F-FDG PET/CT.
In the brain, 68Ga-FAPI PET/CT depicted significantly more metastases than 18F-FDG PET/CT (72% compared to 31%) using MRI as a reference. 68Ga-FAPI PET/CT similarly outperformed 18F-FDG PET/CT in detecting bone metastases (109 vs 91) and pleural metastases (66 vs 35).
The authors conclude that “lung cancer is a gallium 68 (68Ga)–labeled fibroblast-activation protein inhibitor (FAPI)–avid tumor, and 68Ga-FAPI PET/CT showed some superiorities to fluorine 18 (18F)–labeled fluorodeoxyglucose (FDG) PET/CT in the detection of suspected metastases to the lymph nodes, brain, bone, and pleura.”
The added that other studies (Kratochwil et al) have demonstrated similar findings, suggesting that 68Ga-FAPI PET/CT may help detect early-stage lung cancer as well as help guide treatment decisions.
Call for Papers
ARO is seeking original case reports, research articles, and review articles on innovative topics offering practical applications in radiation oncology. Manuscripts undergo a double-blinded external peer review process, and there is no submission fee.
- First Clinical Results Published for 177Lu-rhPSMA-10.1 in mCRPC Trial
- Opaganib Shown to Protect Against Radiation-Induced Lung Inflammation
- Fusion Licenses Actinium-Based PSMA Targeted Radiotherapy From Heidelberg University and Euratom
- Future of Theranostics in Neurooncology Looks Promising With Recent Advancements
- First Cellular Therapy for Unresectable or Metastatic Melanoma Receives FDA Approval